Tradestie Institutional Equity Comparison Engine
PVLA vs MLYS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PVLA Overall Edge
PVLA Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palvella Therapeutics, Inc. Common Stock (PVLA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PVLA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MLYS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro) against MLYS sits in BREAKDOWN (39th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PVLA N/M vs MLYS N/M Fwd P/E
Growth & Margin Winner
PVLA
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
PVLA
1Y +80.2% vs -66.6% ยท 52W Pos 68% vs 1%
Options & Structure Winner
PVLA
CONSOLIDATION (2nd %ile IV) vs BREAKDOWN (39th %ile IV)
PVLA
NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap
$2.2B
1M Return
+20.56%
1Y Return
+80.16%
Forward P/E
N/M
Unified AI Score
48.2 / 100
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
MLYS
NASDAQ
Mineralys Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$14.79
-3.52% 1D
Market Cap
$1.4B
1M Return
-27.14%
1Y Return
-66.61%
Forward P/E
N/M
Unified AI Score
60.1 / 100
BUY
Tech 73.0
Fund 68.0
Flow 69.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PVLA +80.16%
MLYS -66.61%
Spread: +146.77 pp (PVLA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PVLA TTM Op. Margin: 0.0%
MLYS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs MLYS. Trailing 12-month operating profitability (PVLA 0.0% vs MLYS 0.0%) and valuation multiples (PVLA N/M vs MLYS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PVLA | MLYS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.2B | $1.4B | Larger Scale | PVLA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -63.4% | -68.5% | Higher ROE | PVLA |
| 52-Week Range Position Momentum | 68% ($72โ$180) | 1% ($15โ$47) | Stronger Trend | PVLA |
| Beta / 30D Volatility Risk Regime | 1.66ฮฒ ยท 75% Vol | 1.70ฮฒ ยท 89% Vol | Lower Realized Risk | PVLA |
| Unified Institutional Score Composite Signal | 48.2 / 100 (HOLD) | 60.1 / 100 (BUY) | Higher Composite | MLYS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PVLA vs MLYS Buy Guide
PVLA
CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
2nd %ile
IV Regime
Compressed (<25th %ile)
MLYS
BREAKDOWN
119d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
39th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PVLA nor MLYS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.